Sandbox Reserved 1482: Difference between revisions

Revision as of 17:28, 3 March 2019 view source Alexia Benoit (talk \| contribs) 50 edits No edit summary ← Older edit		Revision as of 17:30, 3 March 2019 view source Alexia Benoit (talk \| contribs) 50 edits No edit summary Newer edit →
Line 98:		Line 98:
	The main medication to treat hemophilia A is concentrated factor VIII protein, called “clotting factor”. Getting this “clotting factor” is therefore a major concern for hemophilia-affected people <ref name="Srivastava" />.		The main medication to treat hemophilia A is concentrated factor VIII protein, called “clotting factor”. Getting this “clotting factor” is therefore a major concern for hemophilia-affected people <ref name="Srivastava" />.

	Nowadays, recombinant coagulation factor VIII products~~, which~~ are developed in ~~a lab~~ through the use of DNA technology <ref name="El" /><ref name="toole" />. For instance, Toole and colleagues have created a biologically fully active factor with improved heterologous expression efficiency by deleting the B-domain from the native human factor VIII <ref name="toole" />.		Nowadays, recombinant coagulation factor VIII products are developed in labs through the use of DNA technology <ref name="El" /><ref name="toole" />. For instance, Toole and colleagues have created a biologically fully active factor with improved heterologous expression efficiency by deleting the B-domain from the native human factor VIII <ref name="toole" />.

Navigation menu